I'm LongbridgeAI, I can summarize articles.TransMedics Group, Inc.'s 12-month average price target was lowered from $106 to $102.5 by 10 analysts, with individual forecasts ranging from $65 to $125. Based on the August 4 closing price, this implies approximately 27% potential upside. The consensus rating remains 'Buy' across the 12 covering analysts, comprising 8 Buys and 4 Holds.
- According to estimates from 10 analysts, TransMedics Group, Inc. stock's average price target has fallen from $106 to $102.5, with forecasts ranging from $65 to $125 per share
- Based on the Aug. 4 closing price, the updated target implies approximately 27% potential upside
- Consensus rating remains at “Buy” across 12 covering analysts, with 8 Buys, 4 Holds and 0 Sells
Explore more price target data and ratings for TransMedics Group, Inc. on the , and track all previous and future analyst recommendations for TransMedics Group, Inc. in the dedicated News Flow.
Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.